<DOC>
	<DOC>NCT00305435</DOC>
	<brief_summary>The purpose of the study is to evaluate the efficacy of starting dose of AMG 531 as measured by platelet counts by cohort dose-escalation design.</brief_summary>
	<brief_title>Safety Study of AMG 531 in Japanese Subjects With ITP</brief_title>
	<detailed_description>The purpose of the study is to evaluate the efficacy of starting dose of AMG 531 as measured by platelet counts by cohort dose-escalation design.</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura, Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<criteria>Japanese patients with diagnosis of ITP according to the diagnostic criteria proposed by Research Committee for Idiopathic Hematopoietic Disorders of the Ministry of health, labor and welfare Documented diagnosis of arterial thrombosis in the previous year; history of venous thrombosis and receiving anticoagulation therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>AMG 531, ITP, Phase 2, Japanese</keyword>
</DOC>